The in vitro activities of imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) and amikacin in combination with cefotaxime, trimethoprimsulfamethoxazole, and each other were tested against 26 Nocardia asteroides strains. The agar dilution method was used for all tests. Synergy was present in 80% of tests with imipenem-trimethoprim-sulfamethoxazole, in 92% of tests with imipenem-cefotaxime, and in 83% of tests with amikacin-trimethoprim-sulfamethoxazole. Indifference was found on rare occasions, and no antagonism was seen.
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Several antibiotics, including amikacin, cefotaxime, and imipenem (formerly imipemide, Nformimidoyl thienamycin, or MK0787), among others, have been shown to be efficacious against Nocardia asteroides (3). The antibiotic combination of trimethoprim-sulfamethoxazole (TMP-SMX) has less activity than the aforementioned agents on a weight basis in vitro but has proven efficacy in vivo and has been advocated as the agent of choice in the therapy of nocardial infections (6) . There have been reports, however, of unsuccessful therapy when single agents have been used, and combination antimicrobial therapy has proven to be superior to single-agent therapy (2, 4) .
In this study, the minimal inhibitory concentrations (MICs) of imipenem, amikacin, cefotaxime, and TMP-SMX for 26 N. asteroides strains were determined by the agar dilution technique. In addition, synergy studies were performed with the following antibiotic combinations: imipenem-TMP-SMX, imipenem-cefotaxime, imipenem-amikacin, amikacin-cefotaxime, and amikacin-TMP-SMX.
The antibiotics used in this study and their sources were as follows: imipenem, Merck Susceptibility testing of N. asteroides has been hampered by the lack of standardized testing because of the many variables encountered in growing the organisms uniformly. Also, there has been poor correlation between antibiotic susceptibility in vitro and antibiotic efficacy in experimental models (1) , owing in part, presumably, to an inoculum effect (5). This is particularly true in the case of the sulfonamides. There is better correlation, however, when lower inocula are used (4).
Several new 1-lactam compounds have been developed which are active against N. asteroides. If sulfonamide therapy alone for nocardial infections either cannot be tolerated because of side effects or proves ineffective, in vitro susceptibility testing in which these 3-lactams are used with a sulfonamide or other agents such as amikacin, ampicillin, and erythromycin may show increased activity. Several authors have had success using combination antimicrobial therapy (2, 4) for nocardial infections.
Several studies have confirmed that imipenem and amikacin are the two most active agents on a weight basis against N. asteroides. The combination of these agents with cefotaxime and TMP-SMX were synergistic in most cases (Table 2). The most effective combination in the 
